<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Flecainide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01195</strong>&#160; (APRD00129)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, withdrawn</td></tr><tr><th>Description</th><td><p>A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Paradoxically, however, in myocardial infarct patients with either symptomatic or asymptomatic arrhythmia, flecainide exacerbates the arrhythmia and is not recommended for use in these patients. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01195/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01195/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01195.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01195.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01195.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01195.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01195.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01195">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Flecainida</td><td>Spanish</td><td>INN</td></tr><tr><td>Flecainidum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Flecainide acetate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000086/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000086/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: RKXNZRPQSOPPRN-UHFFFAOYNA-N</li>
              <li>Monoisotopic Mass: 474.158941118</li>
              <li>Average Mass: 474.3947</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000086">DBSALT000086</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Almarytm</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Apocard</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Tambocor</td><td>3M pharmaceuticals</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/anti-arrhythmia-agents">Anti-Arrhythmia Agents</a></li>
<li><a href="/mesh/voltage-gated-sodium-channel-blockers">Voltage-Gated Sodium Channel Blockers</a></li></ul></td></tr><tr><th>CAS number</th><td>54143-55-4</td></tr><tr><th>Weight</th><td>Average: 414.3427<br>Monoisotopic: 414.137811746</td></tr><tr><th>Chemical Formula</th><td>C<sub>17</sub>H<sub>20</sub>F<sub>6</sub>N<sub>2</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>DJBNUMBKLMJRSA-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C17H20F6N2O3/c18-16(19,20)9-27-12-4-5-14(28-10-17(21,22)23)13(7-12)15(26)25-8-11-3-1-2-6-24-11/h4-5,7,11,24H,1-3,6,8-10H2,(H,25,26)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">N-(piperidin-2-ylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Benzenoids</td></tr><tr><th>Class</th><td>Benzene and Substituted Derivatives</td></tr><tr><th>Subclass</th><td>Benzoic Acid and Derivatives</td></tr><tr><th>Direct parent</th><td>Salicylamides</td></tr><tr><th>Alternative parents</th><td>Benzamides; Benzoyl Derivatives; Phenol Ethers; Alkyl Aryl Ethers; Piperidines; Secondary Carboxylic Acid Amides; Dialkylamines; Carboxylic Acids; Polyamines; Enolates; Alkyl Fluorides; Organofluorides</td></tr><tr><th>Substituents</th><td>phenol ether; benzoyl; alkyl aryl ether; piperidine; secondary carboxylic acid amide; carboxamide group; polyamine; enolate; secondary aliphatic amine; secondary amine; carboxylic acid derivative; carboxylic acid; ether; organohalogen; organofluoride; amine; alkyl halide; alkyl fluoride; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the salicylamides. These are carboxamide derivatives of salicylic acid.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Flecainide is is a class Ic antiarrhythmic agent and as such, it is used for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin.</td></tr><tr><th>Pharmacodynamics</th><td>Flecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics.</td></tr><tr><th>Mechanism of action</th><td>Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. Flecainide is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.</td></tr><tr><th>Absorption</th><td>Nearly complete following oral administration.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>40%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. Flecainide does not undergo any consequential presystemic biotransformation. The two major urinary metabolites are meta-O-dealkylated flecainide (active, but about one-fifth as potent) and the meta-O-dealkylated lactam of flecainide (non-active metabolite).</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Flecainide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00905">Meta-O-dealkylated flecainide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/926">Details</a></td></tr><tr><td>Flecainide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00906">Meta-o-dealkylated lactam</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/927">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>In healthy subjects, about 30% of a single oral dose (range, 10 to 50%) is excreted in urine as unchanged drug. Several minor metabolites (3% of the dose or less) are also found in urine; only 5% of an oral dose is excreted in feces. In patients, free (unconjugated) plasma levels of the two major metabolites are very low (less than 0.05 &#956;g/mL).</td></tr><tr><th>Half life</th><td>20 hours (range 12-27 hours)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral LD50 is 50-498 mg/kg in rat. Symptoms of overdose include nausea and vomiting, convulsions, hypotension, bradycardia, syncope, extreme widening of the QRS complex, widening of the QT interval, widening of the PR interval, ventricular tachycardia, AV nodal block, asystole, bundle branch block, cardiac failure, and cardiac arrest.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th><th>SMPDB ID</th></tr></thead><tbody><tr><td>Flecainide Action Pathway</td><td>Drug action</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00331?highlight%5Bcompounds%5D%5B%5D=DB01195&amp;highlight%5Bproteins%5D%5B%5D=DB01195">SMP00331</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9856</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8605</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7773</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.5307</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.7716</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6687</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8921</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8918</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.5957</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9106</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6853</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6556</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5307</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5538</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.672
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8821
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9968
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5680 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9409
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8474
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Amneal pharmaceutical</li>
<li>Apotex inc</li>
<li>Barr laboratories inc</li>
<li>Ranbaxy laboratories ltd</li>
<li>Roxane laboratories inc</li>
<li>Sandoz inc</li>
<li>Graceway pharmaceuticals llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.3m.com">3M Health Care</a></li>
<li><a href="http://www.alphapharm.com.au">Alphapharm Party Ltd.</a></li>
<li><a href="http://www.amneal.com">Amneal Pharmaceuticals</a></li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li>Barr Pharmaceuticals</li>
<li><a href="http://www.gracewaypharma.com">Graceway Pharmaceuticals</a></li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.ohmlabs.com">Ohm Laboratories Inc.</a></li>
<li><a href="http://www.parpharm.com">Par Pharmaceuticals</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.ranbaxy.com">Ranbaxy Laboratories</a></li>
<li><a href="http://www.roxane.com">Roxane Labs</a></li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Tambocor 150 mg tablet</td><td>5.75USD</td><td>tablet</td></tr><tr><td>Tambocor 100 mg tablet</td><td>4.27USD</td><td>tablet</td></tr><tr><td>Flecainide acetate 150 mg tablet</td><td>3.83USD</td><td>tablet</td></tr><tr><td>Flecainide acetate 100 mg tablet</td><td>2.95USD</td><td>tablet</td></tr><tr><td>Tambocor 50 mg tablet</td><td>2.72USD</td><td>tablet</td></tr><tr><td>Flecainide acetate 50 mg tablet</td><td>1.95USD</td><td>tablet</td></tr><tr><td>Tambocor 100 mg Tablet</td><td>1.19USD</td><td>tablet</td></tr><tr><td>Apo-Flecainide 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Tambocor 50 mg Tablet</td><td>0.6USD</td><td>tablet</td></tr><tr><td>Apo-Flecainide 50 mg Tablet</td><td>0.41USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>melting point</td><td>228-229</td><td>Bmitt, E.H. and Brown, W.R.; U.S. Patent 3,900,481; August 19,1975; assigned to Riker Laboratories, Inc.</td></tr><tr><td>water solubility</td><td>48.4 mg/mL at 37 &#176;C (acetate form)</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>3.78</td><td>MANNHOLD,R ET AL. (1990)</td></tr><tr><td>pKa</td><td>9.3</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>3.24e-02 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.98</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>3.19</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4.1</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>13.68</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>9.62</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>59.59</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>9</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>88.4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>35.92</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>2</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p>Bmitt, E.H. and Brown, W.R.; U.S. Patent 3,900,481; August 19,1975; assigned to Riker Laboratories, Inc.</p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=3900481A&amp;tbm=pts" target="_blank">US3900481A <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Gill JS, Mehta D, Ward DE, Camm AJ: Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. Br Heart J. 1992 Oct;68(4):392-7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1449923">Pubmed</a></li>
	<li>Sakurada H, Hiyoshi Y, Tejima T, Yanase O, Tokuyasu Y, Watanabe K, Motomiya T, Sugiura M, Hiraoka M: [Effects of oral flecainide treatment of refractory tachyarrhythmias] Kokyu To Junkan. 1990 May;38(5):471-6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/2115193">Pubmed</a></li>
	<li>Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL, et al.: Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991 Mar 21;324(12):781-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/1900101">Pubmed</a></li>
	<li>Greenberg HM, Dwyer EM Jr, Hochman JS, Steinberg JS, Echt DS, Peters RW: Interaction of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in <span class="caps">CAST</span> I. Br Heart J. 1995 Dec;74(6):631-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/8541168">Pubmed</a></li>
	<li>Gasparini M, Priori SG, Mantica M, Napolitano C, Galimberti P, Ceriotti C, Simonini S: Flecainide test in Brugada syndrome: a reproducible but risky tool. Pacing Clin Electrophysiol. 2003 Jan;26(1  Pt 2):338-41. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12687841">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Drug</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?drug:D07962" target="_blank">D07962 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07001" target="_blank">C07001 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3356" target="_blank">3356 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46508078" target="_blank">46508078 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.3239.html" target="_blank">3239 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>BindingDB</td><td><a class="wishart-link-out" href="http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50131434" target="_blank">50131434 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000518" target="_blank">DAP000518 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA449646" target="_blank">PA449646 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=2560" target="_blank">2560 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2560" target="_blank">2560 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=1966197" target="_blank">1966197 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/flecainide.htm" target="_blank">http://www.rxlist.com/cgi/generic2/flecainide.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/flecainide.html" target="_blank">http://www.drugs.com/cdi/flecainide.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Flecainide" target="_blank">Flecainide <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>C01BC04<ul class="atc-drug-tree"><li><a href="/atc/C#C">C &#8212; CARDIOVASCULAR SYSTEM</a></li><li><a href="/atc/C01#C01">C01 &#8212; CARDIAC THERAPY</a></li><li><a href="/atc/C01B#C01B">C01B &#8212; ANTIARRHYTHMICS, CLASS I AND III</a></li><li><a href="/atc/C01BC#C01BC">C01BC &#8212; Antiarrhythmics, class Ic</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>24:04.04.12</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01195.pdf?1265922740">show</a>(77.1 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Amiodarone may increase the effect and toxicity of flecainide</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00501">Cimetidine</a></td><td>Cimetidine, a moderate CYP2D6 inhibitor, may decrease the metabolism of flecainide.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00476">Duloxetine</a></td><td>Possible increase in the levels of this agent when used with duloxetine</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Flecainide, when administered concomitantly with etravirine, may experience a decrease in serum concentration. It is recommended to monitor flecainide therapy. </td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB08893">Mirabegron</a></td><td>Mirabegron is a moderate CYP2D6 inhibitor and may cause an increase in exposure of CYP2D6 substrates. Monitor concomitant therapy closely. </td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Ritonavir increases the toxicity of the anti-arrhythmic</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00857">Terbinafine</a></td><td>Terbinafine may reduce the metabolism and clearance of Flecainide. Consider alternate therapy or monitor for therapeutic/adverse effects of Flecainide if Terbinafine is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00342">Terfenadine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Increased risk of cardiotoxicity and arrhythmias</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Flecainide. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>